| 2023-03-16 | Sale | CytomX Therapeutics, Inc. CTMX | EVP, Chief Development Officer | 4,257 0.0066% | $1.98 | $8,425 | -20.62% | |
| 2022-07-19 | Sale | CytomX Therapeutics, Inc. CTMX | EVP, Chief Development Officer | 7,463 0.0107% | $1.42 | $10,612 | +10% | |
| 2018-12-18 | Sale | BeiGene, Ltd. BGNE | CMO, Immuno-oncology | 20,282 0.0368% | $133.75 | $2.71M | +0.04% | |
| 2018-12-17 | Sale | BeiGene, Ltd. BGNE | CMO, Immuno-oncology | 19,718 0.0356% | $133.61 | $2.63M | -0.36% | |
| 2018-11-12 | Sale | BeiGene, Ltd. BGNE | CMO, Immuno-oncology | 24,134 0.0443% | $112.73 | $2.72M | +19.28% | |
| 2018-11-09 | Sale | BeiGene, Ltd. BGNE | CMO, Immuno-oncology | 26,444 0.0474% | $120.48 | $3.19M | +8.52% | |
| 2018-11-08 | Sale | BeiGene, Ltd. BGNE | CMO, Immuno-oncology | 29,422 0.0529% | $126.07 | $3.71M | +4% | |
| 2018-08-23 | Sale | BeiGene, Ltd. BGNE | CMO, Immuno-oncology | 11,538 0.0205% | $169.12 | $1.95M | -21.36% | |
| 2017-11-13 | Sale | BeiGene, Ltd. BGNE | CMO, Immuno-oncology | 7,202 0.0158% | $82.96 | $597,494 | +92.95% |